Axsome Therapeutics annual ebitda
2022
2023
2024
2025
Axsome Therapeutics EBITDA Growth & History (AXSM)
Axsome Therapeutics's calculated EBITDA was −$159.9M for fiscal 2025.
View full Axsome Therapeutics company overviewAxsome Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$159.9M | $113.8M | — |
| 2024 | 2024-12-31 | −$273.6M | −$48.6M | — |
| 2023 | 2023-12-31 | −$225.0M | −$49.6M | — |
| 2022 | 2022-12-31 | −$175.4M | — | — |
Axsome Therapeutics quarterly ebitda
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$47.9M | −$12.9M | — |
| Q1 2026 | 2026-03-31 | −$61.7M | −$6.4M | — |
| Q4 2025 | 2025-12-31 | −$25.2M | $45.6M | — |
| Q3 2025 | 2025-09-30 | −$44.4M | $16.5M | — |
| Q2 2025 | 2025-06-30 | −$35.0M | $41.3M | — |
| Q1 2025 | 2025-03-31 | −$55.3M | $10.3M | — |
| Q4 2024 | 2024-12-31 | −$70.9M | $25.7M | — |
| Q3 2024 | 2024-09-30 | −$60.9M | −$510,000 | — |
| Q2 2024 | 2024-06-30 | −$76.3M | −$12.9M | — |
| Q1 2024 | 2024-03-31 | −$65.6M | −$60.8M | — |
| Q4 2023 | 2023-12-31 | −$96.5M | −$55.8M | — |
| Q3 2023 | 2023-09-30 | −$60.4M | −$22.2M | — |
| Q2 2023 | 2023-06-30 | −$63.4M | — | — |
| Q1 2023 | 2023-03-31 | −$4.7M | — | — |
| Q3 2022 | 2022-09-30 | −$40.7M | — | — |
| Q2 2022 | 2022-06-30 | −$38.2M | — | — |
Axsome Therapeutics ebitda trends
Across the available reported history, Axsome Therapeutics's ebitda increased from −$273.6M to −$159.9M, a change of $113.8M. The latest reported quarter, Q2 2026, shows −$47.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axsome Therapeutics filings at SEC.gov ↗